Genetics of Response to Canagliflozin (GRC) Study: Rationale, Design, and Pharmacodynamic Responses.
A genetic study identified which people respond best to a common diabetes drug, laying groundwork for personalized medication selection.
The GRC study enrolled 402 Amish participants to identify genetic predictors of SGLT2 inhibitor response, revealing 34% heritability of canagliflozin-induced glucosuria and quantifying significant variability in bone, cardiovascular, and metabolic biomarkers. Baseline eGFR was the strongest predictor of glucosuria response, and the study sets the foundation for pharmacogenomics-guided SGLT2 inhibitor prescribing.
What the study was
- Study design
- Prospective pharmacogenomic study
- Population
- Healthy Amish adults (n=402) receiving canagliflozin 300mg/day for 5 days
- Sample size
- 402
- Category
- Genomics/Precision Medicine
- Maturity
- Validated
- Journal
- Clinical and Translational Science
Why it surfaced
Well-powered pharmacogenomic study (n=402) with prospective design in carefully characterized cohort; heritability data and pharmacodynamic characterization of bone/CVD/metabolic biomarkers directly relevant to SGLT2 prescribing precision.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.